Labcorp is a leading global life sciences company that includes contract research and developmental services to the pharmaceutical, medical technology, crop protection and chemical industries.
Posters
Prevalence of Secondary Immunotherapeutic Targets in the Absence of Established Immune Biomarkers in Solid Tumors
SITC 2021 -- Immune checkpoint inhibitor-based therapies have achieved impressive success in the treatment of several cancer types. Predictive immune biomarkers, including PD-L1 by immunohistochemistry (IHC), microsatellite instability (MSI) and tumor mutational burden (TMB) are well established as surrogate markers for immune evasion and tumor-specific neoantigens across many tumors. Positive detection across cancer types varies but overall, approximately 50% of patients test negative for these primary immune biomarkers. In this study, we investigated the prevalence of secondary immune biomarkers outside of PD-L1 IHC, TMB and MSI.